DP13 SAD & MAD in Healthy Male Subjects
- Registration Number
- NCT03046589
- Lead Sponsor
- Damian Pharma AG
- Brief Summary
Primary Objectives:
1. To determine the safety and tolerability of single and multiple oral doses of DP13 in healthy male subjects
2. To assess the pharmacodynamics of single and multiple ascending oral doses as well as dosing regimen of DP13 on suppression of serum aldosterone in healthy male subjects
Secondary Objectives:
1. To determine the single and multiple oral dose pharmacokinetics of DP13 in healthy male subjects
2. To determine the dose-dependent pharmacodynamic selectivity of DP13 in healthy male subjects
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 48
Inclusion Criteria
- BMI between 18.0 and 30.0 kg/m2, inclusive
- body weight between 60 and 95 kg, inclusive
- good health as determined by medical history, physical examination, vital signs assessment, 12-lead ECG, clinical laboratory evaluations
- normal stress response
- sodium value within the normal laboratory reference range
- potassium value within the normal laboratory reference range
- written informed consent
Exclusion Criteria
- unwilling to consent or whose partner is unwilling to consent to use a barrier method of contraception
- blood donation within 3 months prior to screening or plasma donation within 7 days prior to screening or platelet donation within 6 weeks prior to screening
- consumption of more than 28 units of alcohol per week or significant history of alcoholism or drug/chemical abuse within the last 12 months prior to screening
- use of tobacco or nicotine-containing products within 3 months
- use of any of the following within 14 days of first dose: non-prescribed systemic or topical medication; any herbal remedy; any vitamin supplement; any mineral supplement
- receipt of any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes
- receipt or intent to receive: any prescribed systemic or topical medication within 14 days of first dose administration
- an abnormality in heart rate, blood pressure, temperature or respiration rate at screening and prior to first dose that in the opinion of the investigator increases the risk of participating in the study
- a positive urine drugs of abuse screen
- an abnormality in the 12-lead ECG at screening and prior to first dose that in the opinion of the investigator increases the risk of participating in the study
- a medical history of clinically significant ECG abnormalities or a family history of a prolonged QT-interval syndrome
- participation in another clinical study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Treatment Period 1 placebo DP13 capsules (dose level 1 ) and placebo capsules Treatment Period 6 placebo DP13 capsules (dose level 6) and placebo capsules Treatment Period 3 DP13 DP13 capsules (dose level 3) and placebo capsules Treatment Period 4 placebo DP13 capsules (dose level 4) and placebo capsules Treatment Period 1 DP13 DP13 capsules (dose level 1 ) and placebo capsules Treatment Period 2 placebo DP13 capsules (dose level 2) and placebo capsules Treatment Period 4 DP13 DP13 capsules (dose level 4) and placebo capsules Treatment Period 6 DP13 DP13 capsules (dose level 6) and placebo capsules Treatment Period 2 DP13 DP13 capsules (dose level 2) and placebo capsules Treatment Period 3 placebo DP13 capsules (dose level 3) and placebo capsules Treatment Period 5 placebo DP13 capsules (dose level 5) and placebo capsules Treatment Period 5 DP13 DP13 capsules (dose level 5) and placebo capsules
- Primary Outcome Measures
Name Time Method Aldosterone suppression Up to 48 hours after dosing Serum aldosterone concentration
Safety and Tolerability (Clinical signs and symptoms incl ECG, vital signs, electrolytes) Up to 2 weeks after dosing Clinical signs and symptoms incl ECG, vital signs, electrolytes
- Secondary Outcome Measures
Name Time Method Pharmacokinetics (Plasma DP13 concentration) up to 48 hours after dosing Plasma DP13 concentration
Pharmacodynamic selectivity (Plasma hormone concentrations) Up to 48 hours after dosing Plasma hormone concentrations
Trial Locations
- Locations (1)
Covance Clinical Research Unit Ltd
🇬🇧Leeds, United Kingdom